1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Forest Laboratories Acquires Clinical Data

M&A Deal Summary

Forest Laboratories Acquires Clinical Data

On April 14, 2011, Forest Laboratories acquired medical products company Clinical Data for 1.2B USD

Acquisition Highlights
  • This is Forest Laboratories’ 1st transaction in the Medical Products sector.
  • This is Forest Laboratories’ 2nd largest (disclosed) transaction.
  • This is Forest Laboratories’ 2nd transaction in the United States.
  • This is Forest Laboratories’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2011-04-14
Target Clinical Data
Sector Medical Products
Buyer(s) Forest Laboratories
Deal Type Add-on Acquisition
Deal Value 1.2B USD
Advisor(s) J.P. Morgan Securities (Financial)
Cooley (Legal)

Target

Clinical Data

Newton, Massachusetts, United States
Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Forest Laboratories

New York, New York, United States
Category Company
Founded 1956
Sector Medical Products
Employees5,800
Revenue 3.1B USD (2013)
DESCRIPTION

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe.

DEAL STATS #
Overall 2 of 4
Sector: Medical Products M&A 1 of 2
Type: Add-on Acquisition M&A Deals 2 of 4
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 3
Year: 2011 M&A 1 of 1
Size (of disclosed) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-01-01 Cerexa

Oakland, California, United States

Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections.

Buy $480M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-01-08 Aptalis Pharma

Mont-Saint-Hilaire, Quebec, Canada

Aptalis is a leading multinational specialty pharmaceutical company. The Company develops and markets a broad line of prescription products used to treat gastrointestinal diseases and disorders.

Buy $2.9B
Mergr

Solution for

Product

Company

Legal